LEVRON
Breaking The Vicious Cycle
LOG IN
We are developing a novel minimally invasive therapeutic device that provides adaptive treatment for NYHA stage 3 Heart Failure eliminating lung congestion.
About
​Preventing cardiac decompensation, using a closed loop device that shifts fluids from the lung, reduces dyspnea and the cardiac workload
Our vision
Our Team
Extensive R&D leadership positions with 12+ years of medical device experience. Recently spearheaded the R&D of an OEM tissue oximeter device at Casmed (CT, USA) that led to the acquisition of the company by Edwards Lifesciences for over $100M
​
Professor and former dean of the biomedical engineering faculty at the Technion and former president of the International Society for Heart Research Israel group. Prof. Landesberg holds a Phd. In biomedical engineering and an M.D. Cum-Laude both from the Technion
Dr. Eckhouse is the founder and chairman of Alon MedTech ventures, a major player in the Israeli medical eco system, founded and invested in 20+ companies. such as Syneron Medical (acquired for $400M) and Ventor technologies (acquired for $325M)
Prof. Offer Amir, MD, FACC, FESC
Professor of Cardiology, Faculty of Medicine, Hebrew University, Jerusalem.
Director Heart Institute, Hadassah Medical ,Center, Jerusalem, Israel
President, Israel Heart Society
Board Member, Heart Failure Association of the European Society of Cardiology